Ran Nussbaum - May 30, 2024 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director, 10%+ Owner
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
May 30, 2024
Transactions value $
$0
Form type
4
Date filed
6/3/2024, 04:15 PM
Previous filing
Jun 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Stock Option (right to buy) Award $0 +10K $0.00 10K May 30, 2024 Common Stock 10K $46.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.